Skip to content

Connect to Protect Partnerships for Youth Prevention Interventions: Phase II

Connect to Protect (C2P) Partnerships for Youth Prevention Interventions: Phase II

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00103896
Enrollment
16706
Registered
2005-02-16
Start date
2003-09-30
Completion date
2010-10-31
Last updated
2017-03-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV Infection

Keywords

High-risk youth, HIV infected youth, Community mobilization, HIV serosurveys

Brief summary

This is Phase II of a three stage project whose overall goals are to develop viable community-based HIV prevention interventions and to form and maintain the necessary community collaborations to support such Adolescent Trials Network (ATN) research activities. This phase will describe specific locations within high-risk areas where youth, ages 12-24, spend time. HIV risk behaviors, social networking patterns and HIV prevalence among youth at these venues will be assessed by administering anonymous computerized interviews to eligible and willing youth. This information will be shared with community partners during scheduled working group meetings.

Detailed description

This is Phase II of a three stage project whose overall goals are to develop viable community-based HIV prevention interventions and to form and maintain the necessary community collaborations to support such ATN research activities. During this phase, each ATN site will gather additional information within high-risk areas and solicit community partner input to ultimately pinpoint the specific locations where at-risk youths, ages 12-24, may be recruited for interventions. This will be done by the following methods: Venues will be identified by HIV+ youth at the ATN site by participation in an anonymous computerized interview. Site staff will then perform brief venue interviews (BVIs) at selected venues to assess the potential yield of youths 12-24 years old. Community partners will also provide the site staff with information on known high-risk venues. High-risk venues will further be identified by the results of anonymous computerized interviews and HIV assays obtained from eligible and willing youth participants at the venues. The interviews will gather information on HIV risk behaviors, social networking patterns and HIV prevalence among youths at these venues. This information will be shared with community partners during scheduled working group meetings.

Interventions

None listed

Sponsors

National Institute on Drug Abuse (NIDA)
CollaboratorNIH
National Institute of Mental Health (NIMH)
CollaboratorNIH
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
CollaboratorNIH
University of North Carolina, Chapel Hill
Lead SponsorOTHER

Study design

Observational model
ECOLOGIC_OR_COMMUNITY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
12 Years to 24 Years
Healthy volunteers
Yes

Inclusion criteria

Index Subjects: * Documented HIV-infection * Acquisition of HIV after age 9 years * Verbal confirmation of 12-24 years of age * Verbal report of having engaged in sexual activity (vaginal, anal and/or oral sex) within the past 12 months * Ability to understand and willingness to provide informed consent/assent BVI subjects: * Youths who appear to be 12-24 years old HIV Serosurvey subjects at the venues: * Verbal confirmation of 12-24 years of age * Verbal report of having engaged in sexual activity (vaginal, anal and/or oral sex) within the past 12 months * Ability to understand and willingness to provide informed consent/assent

Exclusion criteria

* Visibly distraught and/or emotionally unstable (i.e. depressive mood, exhibiting manic, suicidal or violent behavior, etc.) * Visibly intoxicated or under the influence of psychoactive agents * Clinically presents as acutely ill

Design outcomes

Primary

MeasureTime frameDescription
Ascertain specific community venues where at-risk youth can be recruited for interventions within the high-risk areas identified in the first Phase of the studyOne time assessment at 10 monthsThe outcome measure will be assessed using results from: (a) Phase I mapping; (b) Phase II interviews with HIV-infected youth; and (c) Phase II Brief Venue Interviews (BVIs). Input from community partners and ethnographic procedures will add critical information.
Describe HIV risk behaviors of adolescents and young adults recruited from targeted venuesOne time assessment at 10 monthsThe outcome measure will be assessed by conducting HIV serosurveys at each venue identified with youth whose HIV status is unknown.
Describe social networks of adolescents and young adults recruited from targeted venuesOne time assessment at 10 monthsThe outcome measure will be assessed by conducting HIV serosurveys at each venue identified with youth whose HIV status is unknown.
Describe HIV seroprevalence of adolescents and young adults recruited from targeted venuesOne time assessment at 10 monthsThe outcome measure will be assessed by conducting HIV serosurveys at each venue identified with youth whose HIV status is unknown.
Assess the characteristics of the community-researcher partnershipsOne time assessment at 10 monthsThe outcome measure will be assessed by conducting interviews with C2P staff and their community partners. Questionnaires will be completed by both parties and detailed documentation kept.
Assess quality of the community-researcher partnershipsOne time assessment at 10 monthsThe outcome measure will be assessed by conducting interviews with C2P staff and their community partners. Questionnaires will be completed by both parties and detailed documentation kept.
Assess outcomes of the community-researcher partnershipsOne time assessment at 10 monthsThe outcome measure will be assessed by conducting interviews with C2P staff and their community partners. Questionnaires will be completed by both parties and detailed documentation kept.

Countries

Puerto Rico, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026